Terms: = Prostate cancer AND BCL6, BCL5, 603, 604, ENSG00000113916, ZBTB27, P41182, LAZ3, BCL6A, ZNF51 AND Prognosis
11 results:
1. Antidiabetic Drugs and prostate cancer prognosis in a Finnish Population-Based Cohort.
Vihervuori VJ; Talala K; Taari K; Lahtela J; Tammela TLJ; Auvinen A; Raittinen P; Murtola TJ
Cancer Epidemiol Biomarkers Prev; 2021 May; 30(5):982-989. PubMed ID: 33653815
[TBL] [Abstract] [Full Text] [Related]
2. Systemic Inflammatory Markers Are Predictive of the Response to Brachytherapy in the prostate.
Taussky D; Soulieres D; Chagnon M; Delouya G; Bahig H
Cells; 2020 Sep; 9(10):. PubMed ID: 32977662
[TBL] [Abstract] [Full Text] [Related]
3. Identification of Novel Epigenetic Markers of prostate cancer by NotI-Microarray Analysis.
Dmitriev AA; Rosenberg EE; Krasnov GS; Gerashchenko GV; Gordiyuk VV; Pavlova TV; Kudryavtseva AV; Beniaminov AD; Belova AA; Bondarenko YN; Danilets RO; Glukhov AI; Kondratov AG; Alexeyenko A; Alekseev BY; Klein G; Senchenko VN; Kashuba VI
Dis Markers; 2015; 2015():241301. PubMed ID: 26491211
[TBL] [Abstract] [Full Text] [Related]
4. Comparison of digital image analysis and visual scoring of KI-67 in prostate cancer prognosis after prostatectomy.
Desmeules P; Hovington H; Nguilé-Makao M; Léger C; Caron A; Lacombe L; Fradet Y; Têtu B; Fradet V
Diagn Pathol; 2015 Jun; 10():67. PubMed ID: 26070608
[TBL] [Abstract] [Full Text] [Related]
5. Association of PSCA rs2294008 gene variants with poor prognosis and increased susceptibility to gastric cancer and decreased risk of duodenal ulcer disease.
García-González MA; Bujanda L; Quintero E; Santolaria S; Benito R; Strunk M; Sopeña F; Thomson C; Pérez-Aisa A; Nicolás-Pérez D; Hijona E; Carrera-Lasfuentes P; Piazuelo E; Jiménez P; Espinel J; Campo R; Manzano M; Geijo F; Pellise M; Zaballa M; González-Huix F; Espinós J; Titó L; Barranco L; Pazo-Cid R; Lanas A
Int J Cancer; 2015 Sep; 137(6):1362-73. PubMed ID: 25721731
[TBL] [Abstract] [Full Text] [Related]
6. Chromosome 9p deletion in clear cell renal cell carcinoma predicts recurrence and survival following surgery.
El-Mokadem I; Fitzpatrick J; Bondad J; Rauchhaus P; Cunningham J; Pratt N; Fleming S; Nabi G
Br J Cancer; 2014 Sep; 111(7):1381-90. PubMed ID: 25137021
[TBL] [Abstract] [Full Text] [Related]
7. Evaluation of prediction models for the staging of prostate cancer.
Boyce S; Fan Y; Watson RW; Murphy TB
BMC Med Inform Decis Mak; 2013 Nov; 13():126. PubMed ID: 24238348
[TBL] [Abstract] [Full Text] [Related]
8. Is prostate cancer prevention with selenium all in the genes?
Platz EA
Cancer Prev Res (Phila); 2010 May; 3(5):576-8. PubMed ID: 20424133
[TBL] [Abstract] [Full Text] [Related]
9. prostate cancer in Korean men exhibits poor differentiation and is adversely related to prognosis after radical prostatectomy.
Song C; Ro JY; Lee MS; Hong SJ; Chung BH; Choi HY; Lee SE; Lee E; Kim CS; Ahn H
Urology; 2006 Oct; 68(4):820-4. PubMed ID: 17070360
[TBL] [Abstract] [Full Text] [Related]
10. Percentage of the positive area of bone metastasis is an independent predictor of disease death in advanced prostate cancer.
Noguchi M; Kikuchi H; Ishibashi M; Noda S
Br J Cancer; 2003 Jan; 88(2):195-201. PubMed ID: 12610502
[TBL] [Abstract] [Full Text] [Related]
11. Circulating macrophage colony stimulating factor as a marker of tumour progression.
McDermott RS; Deneux L; Mosseri V; Védrenne J; Clough K; Fourquet A; Rodriguez J; Cosset JM; Sastre X; Beuzeboc P; Pouillart P; Scholl SM
Eur Cytokine Netw; 2002; 13(1):121-7. PubMed ID: 11956031
[TBL] [Abstract] [Full Text] [Related]
